The results demonstrate the feasibility of engineering AAVs with highly specific transduction properties, providing a versatile platform for targeted tumor cell suppression and advancing the development of next-generation, precision gene therapies for cancer.
Abstract
Adeno-associated viral (AAV) vectors are widely used in gene therapy for their versatility and safety, but their broad tropism limits cell-specific applications such as targeting primary or metastatic tumor cells. To address this, we developed AAV-STITCH, a strategy using SpyTag technology to covalently attach polypeptides to the AAV capsid. This allows precise, dose-dependent coupling of an anti-GD2 scFv to a galactose-binding-deficient AAV9-W503A capsid, redirecting tropism specifically to GD2-expressing neuroblastoma (NB) cells. In pseudometastatic xenograft mouse models, AAV-STITCHαGD2 selectively transduced NB tumor cells without transduction of healthy liver tissue. Furthermore, delivery of a suicide gene via AAV-STITCHαGD2 significantly slowed tumor growth and extended survival in mice with subcutaneous and pseudometastatic NB xenografts. When combined with standard-of-care chemotherapy for relapsed NB, AAV-STITCHαGD2 produced robust curative effects. Collectively, these results demonstrate the feasibility of engineering AAVs with highly specific transduction properties, providing a versatile platform for targeted tumor cell suppression and advancing the development of next-generation, precision gene therapies for cancer. A modular AAV platform enables antibody-directed viral tropism through covalent capsid engineering. Selective systemic targeting of neuroblastoma was achieved, allowing efficient suicide-gene delivery with potent antitumor activity and minimal off-target transduction. A modular AAV-STITCH platform enables covalent coupling of scFvs to an infectivity-deficient AAV9 capsid through SpyTag/SpyCatcher chemistry. Systemic administration selectively transduced GD2⁺ neuroblastoma cells while largely abolishing transduction of healthy tissues. AAV-STITCHαGD2-TK produced potent antitumor activity, reducing metastatic tumor burden and prolonging survival after a single treatment. Combining AAV-STITCHαGD2-TK with TOTEM chemotherapy resulted in near-complete suppression of tumor growth, supporting complementary therapeutic mechanisms. A modular AAV-STITCH platform enables covalent coupling of scFvs to an infectivity-deficient AAV9 capsid through SpyTag/SpyCatcher chemistry. Systemic administration selectively transduced GD2⁺ neuroblastoma cells while largely abolishing transduction of healthy tissues. AAV-STITCHαGD2-TK produced potent antitumor activity, reducing metastatic tumor burden and prolonging survival after a single treatment. Combining AAV-STITCHαGD2-TK with TOTEM chemotherapy resulted in near-complete suppression of tumor growth, supporting complementary therapeutic mechanisms. A modular AAV platform enables antibody-directed viral tropism through covalent capsid engineering. Selective systemic targeting of neuroblastoma was achieved, allowing efficient suicide-gene delivery with potent antitumor activity and minimal off-target transduction.
A novel approach to detarget liver transduction is developed by transiently downregulating the expression of key entry factors in this tissue using GalNac-siRNAs prior to AAV9 administration, which blunted hepatic transduction but also redirected the vector to other transduction-permissive tissues.
K. Kubek-Luck, J. Velazquez, Xiao-Rui Yao et al.· Molecular Therapy· 0 citations
Systemic administration of protease-activated masked AAVs enables tissue-specific gene delivery to the liver, while administration of near-infrared-activated masked AAVs provides localized transduction in irradiated regions such as muscles and brain.
Zhi-Ying Zeng, Li-Ying Chang, Jing-Jing Wang et al.· Nature Materials· 1 citation
Adeno-associated virus (AAV) vectors are widely used for gene delivery to the central nervous system, but natural capsid tropism is broad and cell-type restriction is typically imposed transcriptionally using promoters and enhancers that consume packaging capacity and often drive weak expression. Here, we enhance neuro...
Ajay Extross, Ezequiel Marron Fernandez de Velasco, Yun-Gui He et al.· bioRxiv· 0 citations
This study establishes this engineered AAV as a versatile and potent vaccine platform that effectively targets DCs, offering a promising approach for inducing robust and adaptable anti-tumor immunity.
Xin Wei, Xiang Li, Li-Xia Qi et al.· Frontiers in Immunology· 0 citations
Viral vector technologies based on adeno-associated viruses (AAVs) have demonstrated promising ability to deliver genetic cargo to a range of organs in vivo, with several novel candidates showing clinical efficacy in human trials over the past decade. However, naturally occurring AAV serotypes are limited in thei...
Annalucia Darbey, Wenanlan Jin, C. Spicer et al.· BMC Research Notes· 0 citations
The results showed the potential of a combinatorial AAV library for model validation and revealed the human microliver platform-PEG as a reliable system for the development of AAV therapeutics.
Carmen Unzu, Amanda X. Chen, Liliana Mancio-Silva et al.· bioRxiv· 0 citations
We use cookies to run the site and, with your consent, for analytics and to show ads.
See our Cookie Policy.